Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
m |
m |
||
| Line 85: | Line 85: | ||
| Public Comment | | Public Comment | ||
| 2017.09.15 | | 2017.09.15 | ||
| − | | [[Media:QIBA_PET_Amyloid Comments_all resolved.xlsx| Public Comment Resolutions 2018-05-02]] | [[Media:QIBA_PET_Amyloid Profile changes.pdf| Profile changes for | + | | [[Media:QIBA_PET_Amyloid Comments_all resolved.xlsx| Public Comment Resolutions 2018-05-02]] | [[Media:QIBA_PET_Amyloid Profile changes.pdf| Profile changes for Technical Confirmation, 2022-04-15]] |
|- | |- | ||
| [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | | [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | ||
Revision as of 19:43, 15 April 2022
Comments received during Public Comment, Technical Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.